WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review of Recent Advances in Oral Hypoglycemic Agents for the Treatment of Type 2 Diabetes

Atif Khan[1], Shivam Rongpi[2*]

[1].Research Scholar, Mewar University, Gangarar, Chittorgarh, Rajasthan-312901

[2*]Assitant Professor, Department of Pharmacy, Mewar University, Gangarar, Chittorgarh, Rajasthan-312901

A B S T R A C T :

A chronic and progressive metabolic disease marked by insulin resistance and β-cell dysfunction, type 2 diabetes mellitus (T2DM) causes ongoing hyperglycemia and related problems. Over the years, the development of oral hypoglycemic agents (OHAs) to enhance glucose control while reducing negative effects has made significant progress. This paper emphasises recent developments in therapy choices, including SGLT2 inhibitors, DPP-4 inhibitors, and new dual agonists like tirzepatide, classifies the several OHAs now in use, and describes the pathophysiology of T2DM. These newer drugs' cardiovascular and renal advantages have been shown in clinical studies, hence broadening their function beyond glucose control. The paper also addresses continuing issues such medication compliance, side effects, illness progression, and financial constraints. Future paths highlight the significance of integrated digital solutions, oral peptide treatments, and individualised medication. Improving long-term results for T2DM patients depends on ongoing creativity and tailored treatment.

Keywords: Type 2 Diabetes Mellitus, Oral Hypoglycemic Agents, SGLT2 Inhibitors, DPP-4 Inhibitors

Introduction

A chronic metabolic disease marked by insulin resistance and increasing pancreatic beta-cell failure, Type 2 diabetes mellitus (T2DM) causes hyperglycemia. Rising fast over the last two decades, T2DM is now a major public health issue with notable socioeconomic consequences [1]. Reducing the risk of long-term consequences such cardiovascular disease, nephropathy, neuropathy, and retinopathy [2] depends on effective glycemic management.

Especially in the early to intermediate phases of T2DM, oral hypoglycemic medications (OHAs) continue to be the foundation of pharmacological therapy. Although metformin and sulfonylureas are extensively used for decades, their drawbacks—gastrointestinal discomfort, hypoglycemia, and eventual loss of efficacy—have spurred the hunt for more focused, newer treatments [3]. Recent developments in the knowledge of diabetes pathophysiology have opened the door for the creation of creative oral medicines acting by unique mechanisms with the goal of enhancing both efficacy and safety profiles [4].

Representing a paradigm change in T2DM care, new types of OHAs include investigational dual receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors. Apart from glycemic control, these drugs provide other advantages like heart protection and weight reduction [5]. Integrating individualised medicine and combination medicines is becoming more and more important in maximising treatment results for various patient groups as research develops [6].

Emphasising new medication classes, important clinical data, and developing trends influencing the future of T2DM treatment, this paper intends to investigate the most recent developments in oral hypoglycemic therapy.

Pathophysiology of Type 2 Diabetes Mellitus

A complicated interaction of genetic, environmental, and metabolic elements that together produce persistent hyperglycemia gives rise to type 2 diabetes mellitus (T2DM). Insulin resistance and increasing β-cell dysfunction, which disturb glucose homeostasis [7], are hallmark characteristics of T2DM. Usually in peripheral tissues like skeletal muscle and fat, insulin resistance forms, which reduces the capacity to properly absorb and use glucose. Often years before hyperglycemia clinically starts, this malfunction [8] appears.

The decrease in pancreatic β-cell activity and mass, which compromises insulin release, is another important factor in T2DM aetiology. With time, the β-cells fail to make up for the rising insulin needs brought on by peripheral resistance. This causes constant hyperglycemia and low insulin levels [9]. Research has revealed that not only is β-cell failure progressive but also quite irreversible, hence stressing the need of early intervention to save pancreatic function [10].

Apart from insulin resistance and beta-cell failure, higher hepatic glucose production greatly contributes to fasting hyperglycemia in T2DM patients. Hyperglycemia is made much worse as the liver grows less receptive to the inhibitory impact of insulin on gluconeogenesis [11]. Furthermore, the function of the incretin system—including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—has drawn interest. People with T2DM have less incretin action, which leads to poor postprandial insulin release and insufficient glucagon suppression [12].

Emerging studies also point to chronic low-grade inflammation, lipotoxicity, oxidative stress, and adipokines as possible causes of the pathophysiological process of type 2 diabetes. These elements aggravate beta-cell death and interfere with insulin signalling systems, hence compromising glucose control [13]. Pivotal in directing the creation of new oral treatments aiming at particular flaws in the diabetic condition..

Classification of Oral Hypoglycemic Agents

Based on their mechanism of action, which targets several pathophysiological abnormalities in type 2 diabetes mellitus (T2DM), oral hypoglycemic medications (OHAs) are generally classified. These drugs either increase insulin secretion, increase insulin sensitivity, lower hepatic glucose generation, or postpone carbohydrate absorption in the gastrointestinal tract [14].

3.1. Traditional Oral Hypoglycemic Agents

For decades, traditional medications have been the foundation of T2DM treatment. Among them, biguanides—with metformin being the prototype—act mostly by lowering hepatic gluconeogenesis and enhancing peripheral insulin sensitivity. Its effectiveness, safety record, and cardiovascular advantages keep metformin as the first-line pharmacological treatment [15].

Insulin secretagogues are sulfonylureas and meglitinides that activate pancreatic beta-cells to produce insulin. Although sulfonylureas are successful in reducing blood sugar, their usage is sometimes constrained by the danger of hypoglycemia and weight increase [16]. Useful for controlling postprandial glucose fluctuations, meglitinides such repaglinide and nateglinide have shorter action durations [17].

By delaying carbohydrate absorption in the small intestine, alpha-glucosidase inhibitors like acarbose and miglitol help to lower postprandial hyperglycemia. Their use, therefore, is sometimes limited owing to gastrointestinal adverse effects including bloating and flatulence [18].

3.2 Emerging and Novel Classes

New OHAs with better safety profiles and extra therapeutic advantages have emerged in recent years. Inhibitors of dipeptidyl peptidase-4 (DPP-4), such sitagliptin and linagliptin, increase natural incretin levels, hence supporting glucagon suppression and glucose-dependent insulin generation [19]. Weight-neutral and minimal hypoglycemia risk, these drugs are appropriate for combo treatments.

The creation of sodium-glucose co-transporter 2 (SGLT2) inhibitors, which encourage urine glucose excretion by blocking glucose reabsorption in the renal proximal tubules, is another notable achievement. Apart from glycemic control, drugs like empagliflozin and dapagliflozin have shown renal and cardiovascular beneficial benefits [5].

Research is also being done on G-protein-coupled receptor agonists—for example, GPR40, GPR119—glucokinase activators, and dual-acting compounds like GIP/GLP-1 receptor agonists with oral delivery promise. By addressing several metabolic pathways, these new classes seek to fulfil unmet T2DM therapy demands [20].

This changing categorisation of OHAs shows the movement from a more thorough, pathophysiology-driven approach in T2DM management to one based only on glucose-lowering tactics.

Recent Advances in Oral Hypoglycemic Agents

Focusing not only on glucose control but also on lowering cardiovascular and renal risks, recent advances in oral hypoglycemic agents (OHAs) have greatly increased the therapy possibilities for type 2 diabetic mellitus (T2DM) [21].

SGLT2 Inhibitors
Empagliflozin and dapagliflozin among others, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce blood sugar by increasing urine glucose excretion. Apart from glycemic control, they help with renal and cardiovascular protection, lower blood pressure, and aid in weight reduction [22][5].

DPP-4 Inhibitors
Inhibitors of dipeptidyl peptidase-4 (DPP-4), such sitagliptin and linagliptin, increase glucose-dependent insulin release by extending incretin hormone action. Weight-neutral and minimal hypoglycemia risk, these drugs are appropriate for long-term treatment [19][23].

Dual GIP/GLP-1 Agonists

Though now injectable, dual GIP/GLP-1 receptor agonist Tirzepatide has motivated attempts to create oral formulations with comparable metabolic advantages, including better glycemic management and notable weight loss [24][25].

New Targets: Glucokinase Activators and GPCRs
Under development for its effects on insulin release and incretin release, G-protein-coupled receptor (GPCR) agonists such as GPR40 and GPR119 [26]. Glucokinase activators and selective PPAR modulators also seek to increase insulin sensitivity and glycemic management with less negative consequences than previous medications [27].

With encouraging results outside glycemic control alone, these developments reflect a move towards personalised, multi-targeted diabetes treatment.

Clinical Evidence and Comparative Effectiveness

Current treatment algorithms for type 2 diabetic mellitus (T2DM) have been much shaped by the evaluation of oral hypoglycemic agents (OHAs) depending on large-scale clinical trials. Recent medication classes beyond glycemic control have been shown in comparative efficacy studies and cardiovascular outcome trials (CVOTs) to provide important insights on their real-world utility, safety, and extra advantages [28].

Across several studies, SGLT2 inhibitors have shown consistent renal and cardiovascular protection. Among T2DM patients with known cardiovascular illness, empagliflozin in the EMPA-REG OUTCOME trial lowered the risk of cardiovascular death by 38% and heart failure hospitalisation by 35% [5]. Likewise, the DECLARE-TIMI 58 study with dapagliflozin and the CANVAS programme with canagliflozin verified notable advantages in lowering heart failure-related results and maintaining renal function [22][29]. These effects are mostly unrelated to their glucose-lowering impact, which makes SGLT2 inhibitors a preferable option for patients with high cardiorenal risk.

Though the results are more neutral in comparison, DPP-4 inhibitors have also been subjected to thorough CVOT investigation. For example, the TECOS study for sitagliptin and the CARMELINA trial for linagliptin showed cardiovascular safety but no superiority over placebo in lowering major adverse cardiovascular events (MACE) [30][31]. Their ongoing use in some groups, such elderly people or those with renal impairment, is supported by their good safety profile, especially the minimal risk of hypoglycemia and weight neutrality.

Currently available in injectable form, dual GIP/GLP-1 receptor agonist tirzepatide has outperformed semaglutide in the SURPASS trials [24] in terms of glycemic and weight reduction effects. Though not yet available as an oral medication, its mechanism and efficacy are paving the ground for future oral dual agonists that could deliver similar effects with better patient adherence. Preliminary research points to possible oral peptide formulations using sophisticated delivery systems [25].

Network meta-analyses have helped to clarify even more the hierarchy of efficacy among OHAs. While DPP-4 inhibitors have great tolerability and moderate efficacy, SGLT2 inhibitors and GLP-1 receptor agonists often demonstrate better cardiovascular and renal outcomes. Such comparison statistics help to advise individualised treatment choices by balancing efficacy, safety, and concomitant conditions in particular patients [32].

Challenges and Future Directions

Though much has been done to create oral hypoglycemic drugs (OHAs), there are still issues to be resolved in type 2 diabetic mellitus (T2DM) management. The progressive character of T2DM, which sometimes calls for the inclusion of several medications over time because of decreased beta-cell function, is a big challenge. Even more recent groups like as SGLT2 and DPP-4 inhibitors cannot stop disease progression, hence stressing the demand for drugs aimed at disease-modifying pathways [33].

Effective glycemic management without sacrificing patient safety is another difficulty. Adverse effects including genitourinary infections with SGLT2 inhibitors, gastrointestinal discomfort with some medications, and uncommon dangers like pancreatitis or heart failure with others limit broad use or call for careful management in specific populations [34]. Furthermore, inter-individual variation in drug response shaped by genetic, lifestyle, and microbiome-related elements complicates standard treatment methods [35].

Especially with polypharmacy and concomitant diseases like hypertension, obesity, and cardiovascular disease, patient adherence is a continuing problem. Poor adherence, adverse effects, or financial constraints cause many patients, especially in low- and middle-income countries where newer OHAs may not be easily accessible, to miss long-term glycemic goals.

Future avenues in OHA research are multi-target medications, oral peptide delivery methods, and individualised medicine strategies. Active research on oral formulations of dual GIP/GLP-1 agonists and GLP-1 receptor agonists aims to combine effectiveness, safety, and simplicity of use [25]. Supported by pharmacogenomics and digital health technologies, precision medicine has the possibility to customise treatments to fit specific patient profiles, hence enhancing results and reducing negative consequences [37].

When combined with current medication, artificial intelligence (AI)-driven clinical decision support systems and real-time glucose monitoring technologies could also improve treatment optimisation [38]. Over the long run, a change towards medications that alter the gut-brain-pancreas axis, beta-cell regeneration, or immunological regulation might change diabetes therapy paradigms beyond present glucose-centric ones [13].

Conclusion

The evolution of new oral hypoglycemic medications (OHAs) that go beyond glucose control to provide cardiorenal protection, weight advantages, and better patient outcomes has profoundly changed the type 2 diabetic mellitus (T2DM) therapy landscape. Drug classes include SGLT2 inhibitors, DPP-4 inhibitors, and the rise of dual agonists have changed therapeutic approaches and moved us nearer to mechanism-based, individualised treatment. But the trip is far from finished. The universal efficacy of these treatments is still hampered by issues with illness progression, negative effects, compliance, cost, and personal variation. Looking forward, developments in drug delivery, precision medicine, and integrated digital health tools offer hope for enhancing treatment strategies and strengthening long-term disease management. Optimising the function of OHAs in the future of diabetes treatment will depend on ongoing research, real-world evidence creation, and patient-centered care.

Acknowledgements

The Author thanks everyone who contributed to this research work.

REFERENCE

1. International Diabetes Federation.
2. IDF Diabetes Atlas, 10th ed.; Brussels, Belgium: IDF, 2021.American Diabetes Association. Standards of Medical Care in Diabetes—2024.
3. Diabetes Care. 2024;47(Suppl 1):S1-S291.Bailey CJ. Metformin: historical overview.
4. Diabetologia. 2017;60(9):1566–1576.Nauck MA, Meier JJ. Incretin-based therapies: where will we be 50 years from now?
5. Diabetologia. 2019;62(7):1216–1223.Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
6. N Engl J Med. 2015;373(22):2117–2128.DeFronzo RA, et al. Combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors in T2DM: rationale and evidence.
7. Diabetes Care. 2020;43(5):1133–1143.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes.
8. Nature. 2006;444(7121):840–846.DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links.
9. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–1287.Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes.
10. J Clin Invest. 2006;116(7):1802–1812.Butler AE, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes.
11. Diabetes. 2003;52(1):102–110.Gastaldelli A, et al. Effect of pioglitazone on hepatic fat content and insulin sensitivity in type 2 diabetic patients.
12. Hepatology. 2006;44(4):846–857.Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
13. Am J Physiol Endocrinol Metab. 2004;287(2):E199–E206.Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease.
14. Nat Rev Immunol. 2011;11(2):98–107.Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach.
15. Diabetes Care. 2015;38(1):140–149.Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes.
16. Diabetol Metab Syndr. 2013;5(1):6.Kalra S, Aamir AH, Raza A. Managing sulfonylurea therapy in type 2 diabetes: A position statement.
17. J Pak Med Assoc. 2015;65(9):1025–1027.Lebovitz HE. Insulin secretagogues: old and new.
18. Diabetes Rev. 1999;7(3):139–153.Chiasson JL, et al. Acarbose for the prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial.
19. Lancet. 2002;359(9323):2072–2077.Gallwitz B. Clinical use of DPP-4 inhibitors.
20. Front Endocrinol (Lausanne). 2019;10:389.Lin DC-H, et al. Targeting metabolic pathways in type 2 diabetes: emerging strategies.
21. Nat Rev Drug Discov. 2021;20(11):825–844.Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., ... & Buse, J. B. (2022). Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
22. Diabetes Care, 45(11), 2753–2786. Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., ... & CANVAS Program Collaborative Group. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes.
23. New England Journal of Medicine, 377(7), 644–657.Scheen, A. J. (2010). DPP-4 inhibitors in the management of type 2 diabetes: a critical review.
24. Drugs, 70(8), 1073–1088. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & Tirzepatide SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.
25. New England Journal of Medicine, 385(6), 503–515. Drucker, D. J. (2020). Advances in oral peptide therapeutics.
26. Nature Reviews Drug Discovery, 19(4), 277–289. Shah, P., Vella, A., & Basu, R. (2020). GPR119 agonists: a novel class of antidiabetic agents.
27. Diabetes, Obesity and Metabolism, 22(7), 1010–1018. Matschinsky, F. M., Wilson, D. F., & Glaser, B. (2011). Glucokinase activators: therapeutic potential and mechanistic insights.
28. Diabetes Care, 34(2), 243–252. Buse, J. B., et al. (2020). 2019 Update to: Management of hyperglycemia in type 2 diabetes.
29. Diabetes Care, 43(2), 487–493.Wiviott, S. D., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
30. New England Journal of Medicine, 380(4), 347–357.Green, J. B., et al. (2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.

31. New England Journal of Medicine, 373(3), 232–242. Rosenstock, J., et al. (2019). Cardiovascular safety of linagliptin in type 2 diabetes: CARMELINA trial.

32. JAMA, 321(1), 69–79. Palmer, S. C., et al. (2021). Comparative effectiveness of glucose-lowering drugs on cardiovascular and renal outcomes: A network meta-analysis.

33. The Lancet Diabetes & Endocrinology, 9(10), 653–662. Inzucchi, S. E., et al. (2015). Management of hyperglycemia in type 2 diabetes: A patient-centered approach.

34. Diabetes Care, 38(1), 140–149.Bailey, C. J., & Day, C. (2019). SGLT2 inhibitors: Glucose-lowering agents with cardiovascular benefits.

35. Trends in Endocrinology & Metabolism, 30(6), 407–417.Pearson, E. R. (2019). Personalized medicine in diabetes: The role of 'omics' and clinical factors.

36. Diabetic Medicine, 36(3), 271–277.Bommer, C., et al. (2018). The global economic burden of diabetes in adults aged 20–79 years: A cost-of-illness study.

37. The Lancet Diabetes & Endocrinology, 5(6), 423–430.Dennis, J. M., et al. (2021). Precision medicine in type 2 diabetes: Clinical and research opportunities.

38. Nature Reviews Endocrinology, 17(9), 573–585.Contreras, I., & Vehi, J. (2018). Artificial intelligence for diabetes management and decision support: Literature review. Journal of Medical Internet Research, 20(5), e10775.